Arsenic has been known for centuries for its double-edged potential: a poison and at the same time a therapeutic agent. The name “arsenikon,” meaning “potent,” speaks itself for the pharmaceutical properties of this compound, questioned and analyzed for at least 2000 years. In the last decades, acute promyelocytic leukemia (APL) has evolved from a highly fatal to a curable disease, due to the use of all-trans-retinoic acid and, more recently, arsenic trioxide combinations. The success of these entirely chemo-free regimens increased the awareness of APL and reduced the prevalence of early deaths, which was an impending issue in this disease. Further improvements are expected with the next use of oral arsenic formulations, which will allow a complete outpatient approach, at least in the post-induction settings, further improving patients’ quality of life. The wide use of standardized approaches in APL will also help unravel long-standing open questions, including the pathogenesis, prevention, and treatment of the differentiation syndrome and of short-term organ toxicities. In the long term, the study of survivorship issues, such as fertility and organ-related and psychological damages, in the increasing number of survivors will help further improve their life after APL.

1.
Hillestad
LK
.
Acute promyelocytic leukemia
.
Acta Med Scand
.
1957 Nov 29
;
159
(
3
):
189
94
.
2.
Rowley
JD
,
Golomb
HM
,
Dougherty
C
.
15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia
.
Lancet
.
1977 Mar 5
;
1
(
8010
):
549
50
.
3.
Pandolfi
PP
,
Alcalay
M
,
Fagioli
M
,
Zangrilli
D
,
Mencarelli
A
,
Diverio
D
,
.
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia
.
Embo J
.
1992 Apr
;
11
(
4
):
1397
407
.
4.
Sanz
MA
,
Grimwade
D
,
Tallman
MS
,
Lowenberg
B
,
Fenaux
P
,
Estey
EH
,
.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
.
Blood
.
2019 Apr 11
;
113
(
9
):
1875
91
.
5.
de
Thé
H
,
Chomienne
C
,
Lanotte
M
,
Degos
L
,
Dejean
A
.
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
.
Nature
.
1990 Oct 11
;
347
(
6293
):
558
61
.
6.
Borrow
J
,
Goddard
AD
,
Gibbons
B
,
Katz
F
,
Swirsky
D
,
Fioretos
T
,
.
Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts
.
Br J Haematol
.
1992 Nov
;
82
(
3
):
529
40
.
7.
Borrow
J
,
Solomon
E
.
Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia
.
Baillieres Clin Haematol
.
1992 Oct
;
5
(
4
):
833
56
.
8.
Arber
DA
,
Orazi
A
,
Hasserjian
R
,
Thiele
J
,
Borowitz
MJ
,
Le Beau
MM
,
.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
.
Blood
.
2016 May 19
;
127
(
20
):
2391
405
.
9.
Guo
A
,
Salomoni
P
,
Luo
J
,
Shih
A
,
Zhong
S
,
Gu
W
,
.
The function of PML in p53-dependent apoptosis
.
Nat Cell Biol
.
2000 Oct
;
2
(
10
):
730
6
.
10.
de Thé
H
.
Differentiation therapy revisited
.
Nat Rev Cancer
.
2018 Feb
;
18
(
2
):
117
27
.
11.
Dos Santos
GA
,
Kats
L
,
Pandolfi
PP
.
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia
.
J Exp Med
.
2013 Dec 16
;
210
(
13
):
2793
802
.
12.
Lo-Coco
F
,
Hasan
SK
.
Understanding the molecular pathogenesis of acute promyelocytic leukemia
.
Best Pract Res Clin Haematol
.
2014 Mar
;
27
(
1
):
3
9
.
13.
Kwok
C
,
Zeisig
BB
,
Dong
S
,
So
CW
.
Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells
.
Cancer Cell
.
2006 Feb
;
9
(
2
):
95
108
.
14.
Nasr
R
,
Guillemin
MC
,
Ferhi
O
,
Soilihi
H
,
Peres
L
,
Berthier
C
,
.
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
.
Nat Med
.
2008 Dec
;
14
(
12
):
1333
42
.
15.
Lallemand-Breitenbach
V
,
Jeanne
M
,
Benhenda
S
,
Nasr
R
,
Lei
M
,
Peres
L
,
.
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway
.
Nat Cell Biol
.
2008 May
;
10
(
5
):
547
55
.
16.
Ablain
J
,
Rice
K
,
Soilihi
H
,
de
Reynies
A
,
Minucci
S
,
de
Thé
H
.
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure
.
Nat Med
.
2014 Feb
;
20
(
2
):
167
74
.
17.
Rao
Y
,
Li
R
,
Zhang
D
.
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered
.
Sci China Life Sci
.
2013 Jun
;
56
(
6
):
495
502
.
18.
Hughes
MF
,
Beck
BD
,
Chen
Y
,
Lewis
AS
,
Thomas
DJ
.
Arsenic exposure and toxicology: a historical perspective
.
Toxicol Sci
.
2011 Oct
;
123
(
2
):
305
32
.
19.
Jolliffe
DM
.
A history of the use of arsenicals in man
.
J R Soc Med
.
1993 May
;
86
(
5
):
287
9
.
20.
Antman
KH
.
Introduction: the history of arsenic trioxide in cancer therapy
.
Oncologist
.
2001
;
6
(
Suppl 2
):
1
2
.
21.
Koeffler
HP
.
Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications
.
Blood
.
1983 Oct
;
62
(
4
):
709
21
.
22.
Warrell
RP
Jr
,
Frankel
SR
,
Miller
WH
Jr
,
Scheinberg
DA
,
Itri
LM
,
Hittelman
WN
,
.
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
.
N Engl J Med
.
1991 May 16
;
324
(
20
):
1385
93
.
23.
Huang
M
,
Ye
Y
,
Chen
S
,
Chai
J
,
Lu
J
,
Zhoa
L
,
.
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
.
Blood
.
1988
;
72
(
2
):
567
72
.
Blood. 2016 Dec 29;128(26):3017
.http://dx.doi.org/10.1182/blood.v72.2.567.567[Check Journal Title]
24.
Chen
GQ
,
Zhu
J
,
Shi
XG
,
Ni
JH
,
Zhong
HJ
,
Si
GY
,
.
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
.
Blood
.
1996 Aug 1
;
88
(
3
):
1052
61
.
25.
Chen
GQ
,
Shi
XG
,
Tang
W
,
Xiong
SM
,
Zhu
J
,
Cai
X
,
.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells
.
Blood
.
1997 May 1
;
89
(
9
):
3345
53
.
26.
Lallemand-Breitenbach
V
,
Guillemin
MC
,
Janin
A
,
Daniel
MT
,
Degos
L
,
Kogan
SC
,
.
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
.
J Exp Med
.
1999 Apr 5
;
189
(
7
):
1043
52
.
27.
Rego
EM
,
He
LZ
,
Warrell
RP
Jr
,
Wang
ZG
,
Pandolfi
PP
.
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
.
Proc Natl Acad Sci U S A
.
2000 Aug 29
;
97
(
18
):
10173
8
.
28.
Sanz
MA
,
Grimwade
D
,
Tallman
MS
,
Lowenberg
B
,
Fenaux
P
,
Estey
EH
,
.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
.
Blood
.
2009 Feb 26
;
113
(
9
):
1875
91
.
29.
Cortes
JE
,
Kantarjian
H
,
O’Brien
S
,
Robertson
LE
,
Koller
C
,
Hirsh-Ginsberg
C
,
.
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia
.
Cancer
.
1994 Jun 15
;
73
(
12
):
2946
52
.
30.
Shen
ZX
,
Chen
GQ
,
Ni
JH
,
Li
XS
,
Xiong
SM
,
Qiu
QY
,
.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
.
Blood
.
1997 May 1
;
89
(
9
):
3354
60
.
31.
Soignet
SL
,
Frankel
SR
,
Douer
D
,
Tallman
MS
,
Kantarjian
H
,
Calleja
E
,
.
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
.
J Clin Oncol
.
2001 Sep 15
;
19
(
18
):
3852
60
.
32.
Shen
ZX
,
Shi
ZZ
,
Fang
J
,
Gu
BW
,
Li
JM
,
Zhu
YM
,
.
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
.
Proc Natl Acad Sci U S A
.
2004 Apr 13
;
101
(
15
):
5328
35
.
33.
Estey
E
,
Garcia-Manero
G
,
Ferrajoli
A
,
Faderl
S
,
Verstovsek
S
,
Jones
D
,
.
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
.
Blood
.
2006 May 1
;
107
(
9
):
3469
73
.
34.
Sanz
MA
,
Lo
Coco
F
,
Martín
G
,
Avvisati
G
,
Rayón
C
,
Barbui
T
,
.
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups
.
Blood
.
2000 Aug 15
;
96
(
4
):
1247
53
.
35.
Iland
HJ
,
Bradstock
K
,
Supple
SG
,
Catalano
A
,
Collins
M
,
Hertzberg
M
,
.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
.
Blood
.
2012 Aug 23
;
120
(
8
):
1570
752
; quiz 752
.http://dx.doi.org/10.1182/blood-2012-02-410746
36.
Powell
BL
,
Moser
B
,
Stock
W
,
Gallagher
RE
,
Willman
CL
,
Stone
RM
,
.
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
.
Blood
.
2010 Nov 11
;
116
(
19
):
3751
7
.
37.
Mathews
V
,
Thomas
M
,
Srivastava
VM
,
George
B
,
Srivastava
A
,
Chandy
M
.
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen
.
Haematologica
.
2007 Jul
;
92
(
7
):
994
5
.
38.
Lo-Coco
F
,
Avvisati
G
,
Vignetti
M
,
Thiede
C
,
Orlando
SM
,
Iacobelli
S
,
.
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
.
N Engl J Med
.
2013 Jul 11
;
369
(
2
):
111
21
.
39.
Montesinos
P
,
Bergua
JM
,
Vellenga
E
,
Rayón
C
,
Parody
R
,
de la Serna
J
,
.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
.
Blood
.
2009 Jan 22
;
113
(
4
):
775
83
.
40.
Cicconi
L
,
Platzbecker
U
,
Avvisati
G
,
Paoloni
F
,
Thiede
C
,
Vignetti
M
,
.
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
.
Leukemia
.
2020 Mar
;
34
(
3
):
914
8
.
41.
Abaza
Y
,
Kantarjian
H
,
Garcia-Manero
G
,
Estey
E
,
Borthakur
G
,
Jabbour
E
,
.
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
.
Blood
.
2017 Mar 9
;
129
(
10
):
1275
83
.
42.
Cicconi
L
,
Divona
M
,
Ciardi
C
,
Ottone
T
,
Ferrantini
A
,
Lavorgna
S
,
.
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
.
Leukemia
.
2016 Oct
;
30
(
10
):
1987
92
.
43.
Burnett
AK
,
Russell
NH
,
Hills
RK
,
Bowen
D
,
Kell
J
,
Knapper
S
,
.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
.
Lancet Oncol
.
2015 Oct
;
16
(
13
):
1295
305
.
44.
Adès
L
,
Thomas
X
,
Bresler
AG
,
Raffoux
E
,
Spertini
O
,
Vey
N
,
.
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
.
Haematologica
.
2018 Dec
;
103
(
12
):
2033
9
.
45.
Zhang
X
,
Zhang
H
,
Chen
L
,
Wang
M
,
Xi
J
,
Liu
X
,
.
Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial
.
Trials
.
2018 Sep 5
;
19
(
1
):
476
.
46.
Efficace
F
,
Mandelli
F
,
Avvisati
G
,
Cottone
F
,
Ferrara
F
,
Di
Bona
E
,
.
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes
.
J Clin Oncol
.
2014 Oct 20
;
32
(
30
):
3406
12
.
47.
Efficace
F
,
Breccia
M
,
Avvisati
G
,
Cottone
F
,
Intermesoli
T
,
Borlenghi
E
,
.
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia
.
Leukemia
.
2019 Jul
;
33
(
7
):
1598
607
.
48.
Kutny
MA
,
Alonzo
TA
,
Gerbing
RB
,
Wang
YC
,
Raimondi
SC
,
Hirsch
BA
,
.
Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s oncology group phase III historically controlled trial AAML0631
.
J Clin Oncol
.
2017 Sep 10
;
35
(
26
):
3021
9
.
49.
Creutzig
U
,
Dworzak
MN
,
Bochennek
K
,
Faber
J
,
Flotho
C
,
Graf
N
,
.
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid
.
Pediatr Blood Cancer
.
2017 Aug
;
64
(
8
):
e26461
.http://dx.doi.org/10.1002/pbc.26461
50.
Au
WY
,
Chim
CS
,
Lie
AK
,
Liang
R
,
Kwong
YL
,
Zecca
M
,
.
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
.
Br J Haematol
.
2019 Apr
;
117
(
1
):
130
2
.
51.
Coombs
CC
,
DeAngelis
LM
,
Feusner
JH
,
Rowe
JM
,
Tallman
MS
.
Pseudotumor cerebri in acute promyelocytic leukemia patients on intergroup protocol 0129: clinical description and recommendations for new diagnostic criteria
.
Clin Lymphoma Myeloma Leuk
.
2016 Mar
;
16
(
3
):
146
51
.
52.
Kayser
S
,
Rahmé
R
,
Martínez-Cuadrón
D
,
Ghiaur
G
,
Thomas
X
,
Sobas
M
,
.
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide: an International Collaborative Study
.
Leukemia
.
2020 Feb 19
.http://dx.doi.org/10.1038/s41375-020-0758-4
53.
Lehmann
S
,
Deneberg
S
,
Antunovic
P
,
Rangert-Derolf
Å
,
Garelius
H
,
Lazarevic
V
,
.
Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013
.
Leukemia
.
2017 Jun
;
31
(
6
):
1457
9
.
54.
Rosati
S
,
Breccia
M
,
Gurnari
C
,
Carmosino
I
,
Scalzulli
E
,
Montefusco
E
,
.
Acute promyelocytic leukemia (APL) in very elderly patients: real-life behind protocols
.
Blood
.
2019
;
134
(
Suppl 1
):
3845
.http://dx.doi.org/10.1182/blood-2019-129216[Check Journal Title]
55.
Zhu
HH
,
Hu
J
,
Lo-Coco
F
,
Jin
J
.
The simpler, the better: oral arsenic for acute promyelocytic leukemia
.
Blood
.
2019 Aug 15
;
134
(
7
):
597
605
.
56.
Qian
LZY
.
The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia
.
Chin J Hematol
.
2006
;
27
(
12
):
801
4
.
57.
Wang
L
,
Zhou
G
,
Liu
P
,
Song
J
,
Liang
Y
,
Yan
X
,
.
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia
.
Proc Natl Acad Sci U S A
.
2008 Mar 25
;
105
(
12
):
4826
31
.
58.
Zhu
HH
,
Wu
DP
,
Du
X
,
Zhang
X
,
Liu
L
,
Ma
J
,
.
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
.
Lancet Oncol
.
2018 Jul
;
19
(
7
):
871
9
.
59.
Zhu
HH
,
Huang
XJ
.
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia
.
N Engl J Med
.
2014 Dec 4
;
371
(
23
):
2239
41
.
60.
Zhu
HH
,
Liu
YR
,
Jia
JS
,
Qin
YZ
,
Zhao
XS
,
Lai
YY
.
Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia
.
Blood
.
2018 Jun 28
;
131
(
26
):
2987
9
.
61.
Jiang
H
,
Liang
GW
,
Huang
XJ
,
Jiang
Q
,
Han
S
,
Shi
LW
,
.
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia
.
Leuk Res
.
2015 Dec
;
39
(
12
):
1319
24
.
62.
Chen
Z
,
Guidez
F
,
Rousselot
P
,
Agadir
A
,
Chen
SJ
,
Wang
ZY
,
.
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors
.
Proc Natl Acad Sci U S A
.
1994 Feb 1
;
91
(
3
):
1178
82
.
63.
Ciangola
G
,
Gurnari
C
,
Paterno
G
,
Mirabile
M
,
Angelini
M
,
Lavorgna
S
,
.
STAT5b-RARa-positive acute myeloid leukemia: diagnostic and therapeutic challenges of a rare AML subtype
.
Leuk Res
.
2019 Mar
;
78
:
21
3
.
64.
Noguera
NI
,
Catalano
G
,
Banella
C
,
Divona
M
,
Faraoni
I
,
Ottone
T
,
.
Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies
.
Cancers
.
2019 Oct 18
;
11
(
10
):
1591
.
65.
Goto
E
,
Tomita
A
,
Hayakawa
F
,
Atsumi
A
,
Kiyoi
H
,
Naoe
T
.
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
.
Blood
.
2011 Aug 11
;
118
(
6
):
1600
9
.
66.
Zhu
HH
,
Qin
YZ
,
Huang
XJ
.
Resistance to arsenic therapy in acute promyelocytic leukemia
.
N Engl J Med
.
2014 May 8
;
370
(
19
):
1864
6
.
67.
Lehmann-Che
J
,
Bally
C
,
de Thé
H
.
Resistance to therapy in acute promyelocytic leukemia
.
N Engl J Med
.
2014 Sep 18
;
371
(
12
):
1170
2
.
68.
Tomita
A
,
Kiyoi
H
,
Naoe
T
.
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
.
Int J Hematol
.
2013 Jun
;
97
(
6
):
717
25
.
69.
Iaccarino
L
,
Ottone
T
,
Divona
M
,
Cicconi
L
,
Cairoli
R
,
Voso
MT
,
.
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia
.
Br J Haematol
.
2016 Mar
;
172
(
6
):
909
13
.
70.
Iaccarino
L
,
Ottone
T
,
Alfonso
V
,
Cicconi
L
,
Divona
M
,
Lavorgna
S
,
.
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse
.
Am J Hematol
.
2019 Oct
;
94
(
10
):
1091
7
.
71.
Madan
V
,
Shyamsunder
P
,
Han
L
,
Mayakonda
A
,
Nagata
Y
,
Sundaresan
J
,
.
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
.
Leukemia
.
2016 Aug
;
30
(
12
):
2430
81
.
You do not currently have access to this content.